Overview

Expanded PK and PD of Insulin Glulisine Versus Insulin Aspart in Healthy Volunteers

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to compare the pharmacodynamics (course of the blood glucose-lowering effect and duration of effect) and pharmacokinetics (course of the concentration of study medication in the blood) of a single subcutaneous dose of 0.2 units/kg of insulin glulisine and insulin aspart in a direct head-to-head comparison during two euglycemic glucose clamps in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Profil Institut für Stoffwechselforschung GmbH
Collaborator:
Sanofi
Treatments:
Insulin
Insulin Aspart
Insulin degludec, insulin aspart drug combination
Insulin glulisine
Insulin, Globin Zinc
Insulin, Long-Acting